Prevalence of obesity in patients receiving depot antipsychotics.
Antipsychotic drugs have long been noted to cause pronounced weight gain, and drug-induced obesity can assume major clinical importance in long-term medication in the management of chronic schizophrenia. Obesity is associated with increased morbidity and may reduce compliance, leading to a return of psychotic symptoms. In a survey of 226 patients attending depot neuroleptic clinics in one inner London borough, it was found that the prevalence of clinically relevant obesity was four times that in the general population.
Silverstone
T
T
Medical College, St Bartholomew's Hospital, London.
Smith
G
G
Goodall
E
E
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D005260:Female; D005475:Flupenthixol / Q000009:adverse effects; D005476:Fluphenazine / Q000009:adverse effects; D006801:Humans; D008297:Male; D009765:Obesity / Q000139:chemically induced*; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*; D012923:Social Class
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D005475:Flupenthixol; D005476:Fluphenazine